Contents hide 1 Non-small Cell Lung Cancer 2 Dosage Modifications 2.1 Dose reduction schedule Alectinib is a type of cancer growth blocker called a tyrosine kinase inhibitor. It works by blocking certain chemical messengers that tell cells to grow. This stops or slows down the cancer. Non-small Cell Lung Cancer Indicated for anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test 600 mg PO BID until disease progression or unacceptable toxicity See Administration Dosage Modifications Dose reduction schedule Starting dose: 600 mg PO BID First dose reduction: 450 mg PO BID Second dose … Continue reading Alynni (Alectinib)